3-3--dihexyl-2-2--oxacarbocyanine and Leukemia--Promyelocytic--Acute

3-3--dihexyl-2-2--oxacarbocyanine has been researched along with Leukemia--Promyelocytic--Acute* in 1 studies

Other Studies

1 other study(ies) available for 3-3--dihexyl-2-2--oxacarbocyanine and Leukemia--Promyelocytic--Acute

ArticleYear
Contrasting features of MDR phenotype in leukemias by using two fluorochromes: implications for clinical practice.
    Leukemia research, 2007, Volume: 31, Issue:4

    The expression and activity of P-glycoprotein (Pgp) and multidrug resistance-associated protein (MRP1) were analyzed in 178 leukemia samples. Rhodamine-123 (Rho-123) and DiOC(2) were used as substrate to evaluate efflux pump activity. Chronic myeloid leukemia (CML) exhibited a higher percentage of positivity using Rho-123 than DiOC(2) (p=0.000) as compared to other types of leukemia. Moreover, Rho-123 was able to detected Pgp positive cells in a higher proportion of samples than DiOC(2) samples (p=0.004). Similarly, MRP1 positive cells were best detected by Rho-123 as opposed to DiOC(2) (p=0.003). The co-functionality of Rho-123 and DiOC(2) was observed in 26 out of 105 (24.8%) leukemic samples. Co-expression between Pgp and MRP1 was detected in 30 out of 56 (53.6%) samples. As a whole, when the same samples were analyzed, Rho-123 was able to detect Pgp positive cells in a higher proportion of samples than DiOC(2) (p=0.000). Similarly, MRP1 positive cells were best detected by Rho-123 as opposed to DiOC(2) (p=0.007). Our results support the idea that Rho-123 is the substrate of choice for leukemic cells.

    Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Carbocyanines; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Fluorescent Dyes; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Multidrug Resistance-Associated Proteins; Phenotype; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Rhodamine 123; Tumor Cells, Cultured

2007